RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Reata Pharmaceuticals Stock

Reata Pharmaceuticals Market capitalization 2024

Reata Pharmaceuticals Market capitalization

6.29 B USD

Ticker

RETA

ISIN

US75615P1030

WKN

A2ALQV

In 2024, Reata Pharmaceuticals's market cap stood at 6.29 B USD, a 590.6% increase from the 911.41 M USD market cap in the previous year.

The Reata Pharmaceuticals Market capitalization history

YEARMarket Capitalization (undefined USD)
20221.11
20213.91
20205.06
20193.33
20181.3
20170.64
20160.44
2015-
2014-
2013-

Reata Pharmaceuticals Aktienanalyse

What does Reata Pharmaceuticals do?

Reata Pharmaceuticals Inc is a biopharmaceutical company that was founded in Irving, Texas in 2002. The company develops and markets innovative therapeutics for severe and rare diseases, particularly rare genetic metabolic diseases, neurological diseases, and inflammatory diseases. Reata Pharmaceuticals has a unique business model based on the principle of "platform technology". This means that the company develops various therapeutic approaches based on a patented molecular platform. This platform allows Reata to quickly and efficiently develop new products for different disease areas. An important focus of Reata Pharmaceuticals' activities is the development of therapeutics for rare genetic metabolic diseases. The company has made remarkable progress in this area. In particular, the drug Omaveloxolone, which was developed for the treatment of Friedreich's ataxia, has attracted a lot of attention. This rare disease manifests as progressive spastic paralysis and can eventually lead to death. The drug has shown promising results in a Phase 2 study and is currently in Phase 3 study. Another important area for Reata Pharmaceuticals is inflammatory diseases. The company has developed a product called Bardoxolone Methyl, which is approved for the treatment of chronic kidney disease and pulmonary hypertension. These diseases have a significant impact on the quality of life and life expectancy of patients. Bardoxolone Methyl has shown in clinical studies that it can slow disease progression and significantly improve symptoms. In addition to these two pillars of activity, Reata Pharmaceuticals also has various product candidates for neurological diseases, cancer, and other diseases in the pipeline. The company aims to develop innovative solutions for unmet medical needs and help patients whose needs have not been adequately addressed. The history of Reata Pharmaceuticals is characterized by a successful path as a company with a unique business model. The company aims to play a leading role in the development and marketing of therapeutics for rare and serious diseases. To achieve this, the company has built a strong research and development team and works closely with the academic community. Reata Pharmaceuticals has managed to establish an international network of leading scientists, doctors, and patient organizations. This collaboration is crucial for the successful development and marketing of therapeutics for rare diseases. In summary, Reata Pharmaceuticals Inc is an innovative biopharmaceutical company that uses a unique platform technology for the development of therapeutics for rare and severe diseases. The company has made remarkable progress in the development of therapeutics for rare genetic metabolic diseases and inflammatory diseases and is working on additional products for neurological diseases, cancer, and other diseases. Reata Pharmaceuticals aims to play a leading role in the industry and help patients whose needs have not been adequately addressed. Reata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Reata Pharmaceuticals's Market Capitalization

Reata Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Reata Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Reata Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Reata Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Reata Pharmaceuticals stock

What is the current Reata Pharmaceuticals market capitalization?

The current market capitalization of Reata Pharmaceuticals is 6.29 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Reata Pharmaceuticals.

How has the market capitalization of Reata Pharmaceuticals developed in recent years?

The market capitalization of Reata Pharmaceuticals has increased/decreased by 590.6% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Reata Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Reata Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Reata Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Reata Pharmaceuticals pay?

Over the past 12 months, Reata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Reata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Reata Pharmaceuticals?

The current dividend yield of Reata Pharmaceuticals is .

When does Reata Pharmaceuticals pay dividends?

Reata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Reata Pharmaceuticals?

Reata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Reata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Reata Pharmaceuticals located?

Reata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Reata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Reata Pharmaceuticals from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Reata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Reata Pharmaceuticals in the year 2023?

In the year 2023, Reata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Reata Pharmaceuticals pay out the dividend?

The dividends of Reata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Reata Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Reata Pharmaceuticals

Our stock analysis for Reata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Reata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.